NCT07439653ClinicalTrials.gov
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
Kurz gefasst
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
Phase 1 / Phase 2155 Teilnehmende gesucht9 Studienzentren1 Land
Kategorien
In 1 Register registriert
- ClinicalTrials.govNCT07439653Diesen Eintrag bei ClinicalTrials.gov öffnenSynchronisiert vor 2 Monaten
Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.
Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.
Interesse an dieser Studie?
Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-02-27; recorded start 2026-03-31
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Not stated: Open label (no blinding)Masking is recorded as none (open label)
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 9 other studies in this databaseCounted from the lead sponsor named in the record (TORL Biotherapeutics, LLC)
- Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
An exploratory-stage design for a phase 2 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation0/20
Non-randomised allocation
- Blinding0/20
Open-label
- Control arm0/15
No comparator arm stated in the record
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre5/8
Multi-centre: 3 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A small study: 155 participants (target), run at 9 sites.
How this score is built
- Enrolment21/40
155 participants (target)
- Site count6/25
3 sites
- Country count0/15
Single country
- Planned duration9/10
Planned over about 43 months
- Sponsor scale3/10
TORL Biotherapeutics, LLC has led 10 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Zusammenfassung
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
Erkrankungen
- Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Eignung
| Geschlecht | Alle |
|---|---|
| Alter | 18 Years – Kein Höchstalter |
| Gesunde Freiwillige | Nein |
Eignung im Wortlaut des Registers
Eignung in einfachen Aussagen
Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.
Studiendesign
| Studientyp | Interventionell |
|---|---|
| Phase | Phase 1 / Phase 2 |
| Zuteilung | Nicht randomisiert |
| Interventionsmodell | SEQUENTIAL |
| Primäres Ziel | TREATMENT |
| Verblindung | NONE (0) |
| Teilnahme | 155 Teilnehmende gesucht |
Sponsor und Mitwirkende
- TORL Biotherapeutics, LLC Sponsor
Studienarme und Interventionen
- Part 1: Monotherapy Dose EscalationEXPERIMENTAL
TORL-5-700 Administered once every three weeks
- Part 2: Monotherapy ExpansionEXPERIMENTAL
TORL-5-700 at MTD/RP2D Administered once every three weeks
- Part 3: Combination EvaluationEXPERIMENTAL
TORL-5-700 at MTD/RP2D Administered once every three weeks in combination with another agent
Interventionen
- Arzneimittel TORL-5-700
Part 1: Monotherapy Dose Escalation - TORL-5-700 Administered once every three weeks
- Arzneimittel TORL-5-700 at MTD/RP2D
Part 2: Monotherapy Expansion - TORL-5-700 at Maximum tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) Administered once every three weeks
- Arzneimittel TORL-5-700 at MTD/RP2D in combination with another agent
Part 3: Combination Evaluation - TORL-5-700 at MTD/RP2D administered every three weeks in combination with another agent
Endpunkte
Primärer Endpunkt
Evaluate the safety of TORL-5-700 as a monotherapy
Assessment of adverse events according to NCI-CTCAE Version 5.0
Zeitrahmen though study completion, an average of 2.5 years
Primärer Endpunkt
Assess the antitumor activity of TORL-5-700 as monotherapy
Assess the antitumor activity of TORL-5-700 using Cheson (2014) disease grading criteria
Zeitrahmen though study completion, an average of 2.5 years
Primärer Endpunkt
Evaluate the safety of TORL-5-700 in combination with other agents
Assessment of adverse events according to NCI-CTCAE Version 5.0
Zeitrahmen though study completion, an average of 2.5 years
Primärer Endpunkt
Determine the Maximum Tolerated Dose (MTD)
Determine the MTD by assessing Protocol defined Dose Limiting Toxicities (DLT)
Zeitrahmen 21 days from the start of treatment
Primärer Endpunkt
Determine the Recommended Phase 2 Dose (RP2D)
Determine the RP2D by assessing Protocol defined Dose Limiting Toxicities
Zeitrahmen 21 days from the start of treatment
Sekundärer Endpunkt
Maximum Serum Concentration of TORL-5-700 (Cmax)
Pk assessment
Zeitrahmen though end of study treatment, an average of 5 months
Sekundärer Endpunkt
Maximum Serum Concentration of TORL-5-700 (Cmax) in combination with other agents
Pk assessment
Zeitrahmen though end of study treatment, an average of 5 months
Sekundärer Endpunkt
Terminal Half-life (t1/2) of Serum TORL-5-700
Pk assessment
Zeitrahmen though end of study treatment, an average of 5 months
Sekundärer Endpunkt
Terminal Half-life (t1/2) of Serum TORL-5-700 in combination with other agents
Pk assessment
Zeitrahmen though end of study treatment, an average of 5 months
Sekundärer Endpunkt
Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration
Pk assessment
Zeitrahmen though end of study treatment, an average of 5 months
Sekundärer Endpunkt
Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration in combination with other agents
Pk assessment
Zeitrahmen though end of study treatment, an average of 5 months
Sekundärer Endpunkt
Clearance (CL) of TORL-5-700
Pk assessment
Zeitrahmen though end of study treatment, an average of 5 months
Sekundärer Endpunkt
Clearance (CL) of TORL-5-700 in combination with other agents
Pk assessment
Zeitrahmen though end of study treatment, an average of 5 months
Sekundärer Endpunkt
Volume of distribution of TORL-5-700
PK assessment
Zeitrahmen though end of study treatment, an average of 5 months
Sekundärer Endpunkt
Volume of distribution of TORL-5-700 in combination with other agents
PK assessment
Zeitrahmen though end of study treatment, an average of 5 months
Sekundärer Endpunkt
Immunogenicity of TORL-5-700
Immunogenicity will be measured by incidence of treatment emergent ADAs
Zeitrahmen though end of study treatment, an average of 5 months
Sekundärer Endpunkt
Immunogenicity of TORL-5-700 in combination with other agents
Immunogenicity will be measured by incidence of treatment emergent ADAs
Zeitrahmen though end of study treatment, an average of 5 months
Sekundärer Endpunkt
Assess the preliminary antitumor activity of TORL-5-700 in combination with other agents
Assess the antitumor activity of TORL-5-700 in combination with other agents using Cheson (2014) disease grading criteria
Zeitrahmen though study completion, an average of 2.5 years
Daten
| Startdatum | 31. März 2026 (tatsächlich) |
|---|---|
| Primärer Abschluss | 31. März 2029 (geschätzt) |
| Abschluss | 30. September 2029 (geschätzt) |
| Erstveröffentlichung | 27. Februar 2026 (tatsächlich) |
| Zuletzt aktualisiert | 28. September 2026 |
| Ergebnisse veröffentlicht | Im Registereintrag nicht angegeben |
| Status zuletzt bestätigt | August 2026 |
Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.
Standorte
9 Studienzentren rekrutieren
United States
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| University of Texas Southwestern Medical Center | Dallas | Texas | Rekrutiert |
| Providence Medical Foundation | Fullerton | California | Rekrutiert |
| University of Iowa Health Care | Iowa City | Iowa | Rekrutiert |
| Cancer and Blood Specialty Clinic, Los Alamitos | Los Alamitos | California | Rekrutiert |
| University of California Miami, Sylvester Comprehensive Cancer Center | Miami | Florida | Rekrutiert |
| Sarah Cannon Research Institute | Nashville | Tennessee | Rekrutiert |
| UCLA | Santa Monica | California | Rekrutiert |
| Stanford University | Stanford | California | Rekrutiert |
| Cancer Center of Kansas, Wichita | Wichita | Kansas | Rekrutiert |
Studiendokumente
In diesem Registereintrag sind keine Dokumente verlinkt.
Änderungen im Zeitverlauf
- 28. September 2026
Studienzentrum hinzugefügt
3 sites added (9 total)
69
- 24. August 2026
Studienzentrum hinzugefügt
3 sites added (6 total)
36